Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 103Carcinoma, Renal Cell 70Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 33Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Colorectal Neoplasms 13Carcinoma, Hepatocellular 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

Tomography, Optical Coherence 1Lasers, Solid-State 1Lasers, Dye 1Lasers 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Port-Wine Stain × Everolimus × Clear all
NCT01997255 2016-05-05

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Baylor College of Medicine

Phase 2 Withdrawn

Epilepsy, Glaucoma, Sturge-Weber Syndrome, Port-Wine Stain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡